Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derivative of angiotensin IV developed for its potent cognitive-enhancing properties. Research demonstrates Dihexa acts as a hepatocyte growth factor (HGF) mimetic, binding to the c-Met receptor and activating downstream signaling pathways involved in neuroplasticity and synaptogenesis. Studies indicate Dihexa is approximately seven orders of magnitude more potent than BDNF in promoting dendritic spinogenesis and synaptic connectivity. Animal research shows improvements in spatial learning, memory consolidation, and reversal of cognitive deficits in models of Alzheimer's disease and age-related cognitive decline. The peptide crosses the blood-brain barrier and can be administered orally or intranasally. Research suggests potential applications for neurodegenerative diseases, traumatic brain injury, and age-related cognitive impairment. Dihexa has demonstrated procognitive effects in multiple preclinical models, though human clinical trials have not yet been conducted. The unique HGF/c-Met mechanism distinguishes it from other nootropic peptides.

No clinical trials exist; evidence is limited to rodent behavioral studies, synaptogenesis assays, and mechanistic work largely from a single research group. Human pharmacokinetics, safety, and efficacy are entirely uncharacterized.

In animal work dihexa crosses the blood-brain barrier and shows oral activity; it is proposed to act via the HGF/c-Met receptor system rather than classical neurotransmitter targets. No human half-life or dosing data were found in reliable sources.